CMND CMND
Company Profile ↓Company Overview
CMND (CMND) is a publicly traded company listed on with a market capitalization of $27.82K. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -99.55% |
| 6 Months: | -91.62% |
| 3 Months: | -71.19% |
| 1 Month: | -16.98% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)40.78 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 99.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 1.31M | 1.41M | 1.46M | 3.66M | 1.57M |
| Operating Income | - | -1.31M | -1.41M | -1.46M | -3.66M | -1.57M |
| EBITDA | - | -743.43K | -1.28M | -679.05K | -3.83M | -2.03M |
| Interest Expense | - | 7.87K | 9.19K | -6.24K | 4.11K | 4.23K |
| Pretax Income | - | -763.27K | -1.31M | -685.65K | -3.85M | -2.04M |
| Tax Provision | - | 20.66K | 8.26K | 2.19K | 3.96K | 3.31K |
| Net Income | - | -783.93K | -1.31M | -687.84K | -3.85M | -2.05M |
| Diluted EPS | -95.50 | -62.27 | -100.00 | - | -33.20 | -6.78 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 6.25M | 6.30M | 5.74M | 5.67M |
| Operating Income | - | -6.25M | -6.30M | -5.74M | -5.67M |
| EBITDA | - | -6.77M | -8.54M | -4.79M | -3.72M |
| Interest Expense | - | 14.42K | 10.89K | 36.16K | 19.54K |
| Pretax Income | - | -6.87M | -8.60M | -4.88M | -3.79M |
| Tax Provision | - | 29.86K | 17.37K | 377.97K | 70.44K |
| Net Income | - | -6.89M | -8.62M | -5.25M | -3.86M |
| Diluted EPS | - | -63,440.20 | -5,679.08 | -678.00 | -303.50 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 826.41K | 5.95M | 7.26M | 6.08M |
| Current Assets | - | 434.69K | 5.79M | 7.09M | 5.95M |
| Cash & Equivalents | - | 128.78K | 5.43M | 6.57M | 3.92M |
| Inventory | - | - | - | - | - |
| Receivables | 160.87K | - | - | - | - |
| Total Liabilities | - | 1.93M | 4.97M | 4.15M | 4.89M |
| Current Liabilities | - | 1.93M | 4.97M | 4.13M | 4.89M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 38.39K | 0 | 53.14K | 1.78M |
| Total Equity | - | -1.11M | 983.47K | 3.11M | 1.19M |
| Shares Outstanding | - | 109 | 1.52K | 10.66K | 15.81K |
Cash Flows (Annual)
Figures in USD.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -3.72M | -6.30M | -4.86M | -4.73M |
| Investing Cash Flow | - | -5.56K | -26.23K | -238.10K | -542.02K |
| Financing Cash Flow | - | 511.69K | 11.66M | 6.25M | 2.62M |
| Capital Expenditure | -169.38K | -5.56K | - | - | - |
| Free Cash Flow | - | -3.73M | -6.30M | -4.86M | -4.73M |
| Net Change in Cash | - | -3.22M | 5.34M | 1.16M | -2.65M |
Ratios (Annual)
Figures in %.
| Metric | Oct 2021 | Oct 2022 | Oct 2023 | Oct 2024 | Oct 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 623.4% | -876.6% | -169.1% | -323.4% |
| ROCE % | - | 565.2% | -640.9% | -183.9% | -475.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CMND
Clearmind's CMND-100 trial reaches 160 mg with no serious adverse events - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNc3BSdnZWYXZKV1hXZXd2aU1LUlc1OVdfM3JObS1jLTdMcUVIQUFUczdOaDN6NzVOblRhMHNwM3M5dVZsaGVPUXF6bVJvcnJGaHBNZ1FISmltTms2bDY4dTIzYkEzX2xGaU5EdVVCRXdQMlNFX0xiYWM2N185NHFaeW5tbndPbUhTWExZaV…
Is Clearmind Medicine (NASDAQ:CMND) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOWm5BZnRYZkQ4WkpzdDhpVU56Wlc1TmZlZUJlWUt5d1Zsb0ZEajlESDJnaExQOTQzQTN4NEN4TXJBNTVFTmp1RmNVRm1WLVpIYmF3LXp5Z3lCSHA2WEZ1eXBaSGNtNTZHQkhxVnhFZlpod2ZnTWRCYlg5b2Q3eTAzR0FXMmljU1hKSktOSU…
$CMND stock is up 9% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxNci1ia3EwempSYlJPRFZpT2d6azVsNUZuMUxRRl9LMjBiZ0l6WkRDUkVRM0kxejNTckhxR0J2Ym5DRTNJUnE3b016Z0RINWhuNG9ncV9kZ1ZWNlowZTRjWE9qeUZHOC01cTZ2TEFpem5DcVdQamU5bGpuS3lyQVZOZEhkMFZZVnNCN05KWm…
CMND Stock Jumps As Clearmind Wins Key Trial, IP Milestones - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxPVWFQMkpZRzBqd3V2amVzeEdNbi1NdHNNLTRrQV9GU3NyUmctOFM5eGs0TENPdGpwTXZhX0lsTDU2QzIyVVl3eHdtNG1GR0lTZTBoWGZjb3EyaENMS2VjMGN3a3k2VUVVbkdyRmd5Z2hQb2lydlBPaEJOQU9saHYtZw?oc=5" target="_…
Why Is Clearmind Medicine Stock Sliding On Wednesday? - Benzinga
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxQR284c1hsajJKbnFJWkRtZXhxeERzMjl0ZG05N0RXWllaaGV5dHZqTnloMnpPdFNNemNrOUcxQVN1UUJaYlhKVldJbGszRUxqdUtYX1o2ZEV6WEM0UlowSW1kZGxuNVc2LWRGTUFiaVU1TTJ0dU9zSk1kblBENHFIMzRNMUdCWTQ0SVNRVW…
CMND Stock Set For Biggest Intraday Gains In Over Three Years — Here’s Why Retail Is Eyeing Further Upside - Stocktwits
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPQlp3c2JvRVVyd0NxVkNwaXlCQVpBaTFWYS02VjNEaUZnSnZyeUl0UGhEMnE5LURxcTlXbVRfalJMU216b01iQkdaZEdOanJLTnlVaGdfWERMUlJOUHU4Zkx5VzFIWGJseTJ3dkZVMXVmUTNHSkR2MG95V0hxV1VIUUl2UTFLR2E4eGVQN0…
CMND — Frequently Asked Questions
What is the current share price of CMND?
As of 2026-08-05 17:25 PDT, CMND trades at $1.76 on NASDAQ/NYSE. Its 52-week range is $1.46 to $476.00.
What is the market capitalisation of CMND?
CMND has a market capitalisation of $27.82K on NASDAQ/NYSE.
What is the P/E ratio of CMND?
CMND trades at a trailing price-to-earnings (P/E) ratio of -0.01. Its price-to-book (P/B) ratio is 0.02.
Is CMND a good stock to buy?
This page provides a data-driven analysis of CMND, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.